704 related articles for article (PubMed ID: 22466482)
1. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
2. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
4. Effect of photodynamic therapy on short-wavelength fundus autofluorescence in eyes with acute central serous chorioretinopathy.
Hagen S; Ansari-Shahrezaei S; Smretschnig E; Glittenberg C; Krebs I; Steiner I; Binder S
Retina; 2015 Feb; 35(2):223-30. PubMed ID: 25102195
[TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
6. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
7. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
Reibaldi M; Cardascia N; Longo A; Furino C; Avitabile T; Faro S; Sanfilippo M; Russo A; Uva MG; Munno F; Cannemi V; Zagari M; Boscia F
Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
[TBL] [Abstract][Full Text] [Related]
8. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
[TBL] [Abstract][Full Text] [Related]
9. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
[TBL] [Abstract][Full Text] [Related]
10. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
11. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
[TBL] [Abstract][Full Text] [Related]
13. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
[TBL] [Abstract][Full Text] [Related]
14. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
15. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
16. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
17. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
18. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
[TBL] [Abstract][Full Text] [Related]
19. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
[TBL] [Abstract][Full Text] [Related]
20. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
